Neurological Blood-based Biomarkers and Cognitive Disorders in Critically Ill Survivors.

Launched by UNIVERSITY OF LIEGE · Jul 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the relationship between certain blood markers and cognitive disorders in people who have been critically ill and treated in an Intensive Care Unit (ICU). After spending time in the ICU, many patients experience problems with thinking and memory, known as cognitive disorders. The researchers want to see if certain substances in the blood, which can indicate brain health, can help predict who might develop these issues in the three months following their discharge from the ICU.

To participate in this study, individuals should be French-speaking and have expected to stay in the ICU for at least seven days due to serious conditions like severe infections or respiratory problems. Unfortunately, those with hearing or vision impairments, existing cognitive disorders, or those admitted for neurological issues will not be eligible. Participants can expect to provide blood samples and undergo assessments to help researchers understand the connection between blood markers and cognitive health after a critical illness. This research could lead to better ways to identify and support patients at risk for cognitive challenges after their ICU experience.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Anticipated ICU stay of at least 7 days for sepsis, acute respiratory distress syndrome, severe burns
• • French speaking
• Exclusion Criteria:
• • hearing loss or blindness
• • mental retardation
• • known cognitive disorders or dementia
• • ICU admission for neurological disease
• • refusal